Congenital Bleeding Disorder Clinical Trial
— pathfinder™3Official title:
Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A
Verified date | July 2020 |
Source | Novo Nordisk A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial is conducted globally. The aim of this trial is to evaluate the haemostatic effect of NNC 0129-0000-1003 during surgical procedures in subjects with haemophilia A.
Status | Completed |
Enrollment | 36 |
Est. completion date | December 10, 2018 |
Est. primary completion date | December 10, 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 12 Years and older |
Eligibility |
Inclusion Criteria: - Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.) - Ongoing participation in the pathfinder™2 (NN7088-3859) or the pathfinderTM 4 (NN7088-3861) trial and having received greater than or equal to 5 doses of N8-GP - Undergoing major surgery requiring daily monitoring of FVIII:C (FVIII activity) and wound status for at least 3 days - The patient and/or Legally Acceptable Representative (LAR) is capable of assessing a bleeding episode, keeping an eDiary, capable of home treatment of bleeding episodes and otherwise capable of following the trial procedures Exclusion Criteria: - Known or suspected hypersensitivity to trial product including allergy to hamster protein or related products - Previous withdrawal from the pathfinder™2 (NN7088-3859) or the pathfinderTM 4 (NN7088-3861) trial after administration of trial product, except interruption due to inclusion in this pathfinderTM 3 trial (NN7088-3860) - The receipt of any investigational medicinal product (except N8-GP) within 30 days prior to enrolment into the trial. (For Brazil, only: Participation in a previous clinical trial within one year prior to screening for this trial (Visit 1), unless there is a direct benefit to the research subject, at the Investigator's discretion) - FVIII inhibitors at least 0.6 BU (Bethesda Units)/mL at screening - Previous arterial thrombotic events (e.g. myocardial infarction and intracranial thrombosis) or previous deep venous thrombosis or pulmonary embolism (as defined by available medical records) - Immune modulating or chemotherapeutic medication - Any disease (liver, kidney, inflammatory and mental disorders included) or condition which, according to the Investigator's judgement, could imply a potential hazard to the patient, interfere with trial participation or trial outcome - Unwillingness, language or other barriers precluding adequate understanding and/or cooperation |
Country | Name | City | State |
---|---|---|---|
Australia | Novo Nordisk Investigational Site | Camperdown | New South Wales |
Australia | Novo Nordisk Investigational Site | Parkville | Victoria |
Australia | Novo Nordisk Investigational Site | South Brisbane | Queensland |
Brazil | Novo Nordisk Investigational Site | Campinas | Sao Paulo |
Bulgaria | Novo Nordisk Investigational Site | Sofia | |
Croatia | Novo Nordisk Investigational Site | Split | |
Croatia | Novo Nordisk Investigational Site | Zagreb | |
Denmark | Novo Nordisk Investigational Site | Århus N | |
Denmark | Novo Nordisk Investigational Site | København Ø | |
France | Novo Nordisk Investigational Site | Bron Cedex | |
France | Novo Nordisk Investigational Site | Le Kremlin Bicetre | |
France | Novo Nordisk Investigational Site | Nantes Cedex 1 | |
France | Novo Nordisk Investigational Site | Paris | |
Germany | Novo Nordisk Investigational Site | Berlin | |
Germany | Novo Nordisk Investigational Site | Bonn | |
Germany | Novo Nordisk Investigational Site | Frankfurt/M. | |
Germany | Novo Nordisk Investigational Site | Hannover | |
Germany | Novo Nordisk Investigational Site | Homburg | |
Germany | Novo Nordisk Investigational Site | München | |
Hungary | Novo Nordisk Investigational Site | Budapest | |
Hungary | Novo Nordisk Investigational Site | Debrecen | |
Israel | Novo Nordisk Investigational Site | Tel-Hashomer | |
Italy | Novo Nordisk Investigational Site | Milano | |
Italy | Novo Nordisk Investigational Site | Udine | |
Italy | Novo Nordisk Investigational Site | Vicenza | |
Japan | Novo Nordisk Investigational Site | Kashihara-shi, Nara | |
Japan | Novo Nordisk Investigational Site | Shinjuku-ku, Tokyo | |
Japan | Novo Nordisk Investigational Site | Suginami-ku, Tokyo | |
Japan | Novo Nordisk Investigational Site | Tokyo | |
Malaysia | Novo Nordisk Investigational Site | Kuala Lumpur | |
Malaysia | Novo Nordisk Investigational Site | Selangor Darul Ehsan | |
Netherlands | Novo Nordisk Investigational Site | Groningen | |
Netherlands | Novo Nordisk Investigational Site | Rotterdam | |
Norway | Novo Nordisk Investigational Site | Oslo | |
Spain | Novo Nordisk Investigational Site | Madrid | |
Spain | Novo Nordisk Investigational Site | Málaga | |
Sweden | Novo Nordisk Investigational Site | Malmö | |
Switzerland | Novo Nordisk Investigational Site | Genève 14 | |
Switzerland | Novo Nordisk Investigational Site | Lausanne | |
Switzerland | Novo Nordisk Investigational Site | Zürich | |
Taiwan | Novo Nordisk Investigational Site | Changhua | |
Taiwan | Novo Nordisk Investigational Site | Taipei | |
Turkey | Novo Nordisk Investigational Site | Adana | |
Turkey | Novo Nordisk Investigational Site | Bornova-IZMIR | |
Turkey | Novo Nordisk Investigational Site | Samsun | |
United Kingdom | Novo Nordisk Investigational Site | Basingstoke | |
United Kingdom | Novo Nordisk Investigational Site | Cardiff | |
United Kingdom | Novo Nordisk Investigational Site | London | |
United Kingdom | Novo Nordisk Investigational Site | London | |
United Kingdom | Novo Nordisk Investigational Site | Oxford | |
United Kingdom | Novo Nordisk Investigational Site | Sheffield | |
United States | Novo Nordisk Investigational Site | Baltimore | Maryland |
United States | Novo Nordisk Investigational Site | Boise | Idaho |
United States | Novo Nordisk Investigational Site | Charleston | South Carolina |
United States | Novo Nordisk Investigational Site | Cincinnati | Ohio |
United States | Novo Nordisk Investigational Site | Houston | Texas |
United States | Novo Nordisk Investigational Site | Iowa City | Iowa |
United States | Novo Nordisk Investigational Site | Long Beach | California |
United States | Novo Nordisk Investigational Site | Nashville | Tennessee |
United States | Novo Nordisk Investigational Site | New Orleans | Louisiana |
United States | Novo Nordisk Investigational Site | Newark | New Jersey |
United States | Novo Nordisk Investigational Site | Norfolk | Virginia |
United States | Novo Nordisk Investigational Site | Orlando | Florida |
United States | Novo Nordisk Investigational Site | Philadelphia | Pennsylvania |
United States | Novo Nordisk Investigational Site | Phoenix | Arizona |
United States | Novo Nordisk Investigational Site | Portland | Oregon |
United States | Novo Nordisk Investigational Site | Sacramento | California |
United States | Novo Nordisk Investigational Site | Spokane | Washington |
United States | Novo Nordisk Investigational Site | Tampa | Florida |
United States | Novo Nordisk Investigational Site | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
United States, Australia, Brazil, Bulgaria, Croatia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Malaysia, Netherlands, Norway, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom,
Tosetto A, Neff A, Lentz SR, Santagostino E, Nemes L, Sathar J, Meijer K, Chowdary P, Shen C, Landorph A, Hampton K. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Haemostatic Effect During Surgery Evaluated by the Four-point Scale, Assessed by the Investigator/Surgeon at the Day of Surgery - Four-point Response Scale: Excellent, Good, Moderate or None | Haemostatic effect during surgery was evaluated on a four-point response scale as 'none', 'moderate', 'good' and 'excellent'. This was assessed after completion of surgery (defined as "last stitch"). Excellent: Better than expected/predicted in this type of procedure. Good: As expected in this type of procedure. Moderate: Less than optimal for the type of procedure but haemostatic response maintained without change of treatment regimen. None: Bleeding due to inadequate therapeutic response with adequate dosing, change of regimen required. |
Assessed by the Investigator/surgeon at the day of surgery | |
Secondary | Average Consumption of N8-GP During Surgery | Average consumption of N8-GP, during surgery is presented. The time during surgery is defined from 'knife to skin' until 'last stitch'. | During surgery, defined as the time from "knife to skin" until "last stitch" | |
Secondary | Haemostatic Effect of N8-GP During the Post-operative Period Days 1-6 | Haemostatic effect during post-operative period days 1-6 as evaluated on a four-point response scale as 'none', 'moderate', 'good' and 'excellent'. Excellent: Better than expected/predicted in this type of procedure. Good: As expected in this type of procedure. Moderate: Less than optimal for the type of procedure but haemostatic response maintained without change of treatment regimen. None: Bleeding due to inadequate therapeutic response with adequate dosing, change of regimen required. |
During the post-operative period, days 1-6 | |
Secondary | Haemostatic Effect of N8-GP During the Post-operative Period Days 7-14 | Haemostatic effect during post-operative period days 1-6 and days 7-14 was evaluated on a four-point response scale as 'none', 'moderate', 'good' and 'excellent'. Excellent: Better than expected/predicted in this type of procedure. Good: As expected in this type of procedure. Moderate: Less than optimal for the type of procedure but haemostatic response maintained without change of treatment regimen. None: Bleeding due to inadequate therapeutic response with adequate dosing, change of regimen required. |
During the post-operative period, days 7-14 | |
Secondary | Average Consumption of N8-GP During the Post-operative Period Days 1-6 | Average consumption of N8-GP during post operative period days 1-6 is presented. Analysis population: Full analysis set included all subjects exposed to the trial drug (N8-GP) and completed surgery. | During the post-operative period, days 1-6 | |
Secondary | Incidence Rate of Inhibitors Against Factor VIII (FVIII) (=0.6 BU/mL) | Incidence rate of inhibitors is the number of newly developed inhibitors per surgery. Development of FVIII inhibitors was measured by a validated Nijmegen modified Bethesda assay. A positive inhibitor test was defined as =0.6 bethesda unit. Number of participants with inhibitors at the end of trial is presented. | during the trial (2-5 weeks) | |
Secondary | Estimated Blood Loss During Surgery | The mean estimated blood loss following surgery is presented. Estimated blood loss (mL) was evaluated post surgery. | During surgery | |
Secondary | Number of Transfusions During the Post-operative Period Days 1-6 | Number of blood product transfusions (transfusion of red blood cells) during the post-surgery period, Days 1-6 is presented. | Post-operative period, days 1-6 | |
Secondary | Length of Stay in the Hospital | Mean number of days stayed at the hospital during the trial. | During the trial (2-5 weeks) | |
Secondary | Number of Days in Intensive Care | Mean number of days in the intensive care due to surgery during the trial is presented. | During the trial (2-5 weeks) | |
Secondary | Adverse Events Reported During the Trial Period | Number of adverse event during the trial is presented. This includes events from the first trial related activity after the patient has signed the informed consent and until the end of trial (earliest at day 14). | During the trial (2-5 weeks) | |
Secondary | Serious Adverse Events Reported During the Trial Period | Number of serious adverse event during the trial is presented. This includes events from the first trial related activity after the patient has signed the informed consent and until the end of trial (earliest at day 14). | During the trial (2-5 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00978380 -
Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725
|
Phase 3 | |
Completed |
NCT02568202 -
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
|
N/A | |
Completed |
NCT01949792 -
A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors
|
Phase 1 | |
Completed |
NCT01205724 -
Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
|
Phase 1 | |
Completed |
NCT01562587 -
Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
|
Phase 1 | |
Completed |
NCT00108797 -
Trial of NovoSeven® in Haemophilia - Joint Bleeds
|
Phase 4 | |
Completed |
NCT01493778 -
Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
|
Phase 3 | |
Completed |
NCT02490787 -
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
|
Phase 1 | |
Completed |
NCT00951405 -
Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors
|
Phase 2 | |
Completed |
NCT01876745 -
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
|
N/A | |
Completed |
NCT02920398 -
A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A
|
Phase 1 | |
Completed |
NCT00984126 -
Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
|
Phase 3 | |
Completed |
NCT01228669 -
Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
|
Phase 1 | |
Completed |
NCT01988532 -
Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia
|
N/A | |
Completed |
NCT01234545 -
Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
|
N/A | |
Completed |
NCT01779921 -
Treatment of Congenital Factor VII Deficiency
|
N/A | |
Completed |
NCT01563471 -
Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02941354 -
Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A
|
Phase 1 | |
Completed |
NCT02241694 -
To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives
|
N/A | |
Completed |
NCT01238367 -
A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543
|
Phase 1 |